PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)

• Status: Terminated
• Trial end date: 2014-04-06
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this protocol is to measure a receptor in the brain using positron emission tomography (PET) that is involved in inflammation.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute of Mental Health (NIMH)

Criteria

• INCLUSION CRITERIA:

Inclusion criteria (healthy control subjects) aged 18 50 years with history/physical exam, ECG, and laboratory tests, plus inclusion criteria listed will be included in the protocol.

1. HIV-seropositive based on ELISA and Western blot (except the HIV-seronegative subjects, who will have ELISA screening).

2. Capable of providing informed consent.

3. Ambulatory at initial visit.

4. If cognitively impaired, the degree of impairment will be MCMD, and not frank HIV-associated dementia.

EXCLUSION CRITERIA:

1. Current psychiatric illness or severe systemic disease based on history and physical exam

2. Current dependence on alcohol or substances other than nicotine.

3. Laboratory results from blood or urine tests that show clinically significant abnormalities.

4. Previous radiation exposure (X-rays, PET scans etc.) that would exceed research limits.

5. Pregnancy and breast feeding.

6. A history of brain disease.

7. Cannot lie on your back for long periods since the pictures will be taken for about 2.5 hours during which time you will have to lie still on the scanner bed.

8. More than moderate hypertension.

9. Positive result on urine screen for illicit drugs.